Creo Medical Group PLC US FDA clearance for MicroBlate(TM) Flex device (8285K)

TIDMCREO

RNS Number : 8285K

Creo Medical Group PLC

07 January 2021

Creo Medical Group plc

("Creo" or the "Company")

US FDA clearance for MicroBlate (TM) Flex devic e

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that it has received 510(k) clearance from the US Food & Drug Administration ('FDA') for its tissue ablation device MicroBlate (TM) Flex .

MicroBlate(TM) Flex is the fourth device within Creo's portfolio of flexible endoscopy devices for the gastrointestinal ('GI') market to receive FDA regulatory clearance, alongside CE marking already received across the range in 2020. The first Creo product to receive FDA clearance, Speedboat(TM) Inject , is being used by clinicians in the UK, EU, US, South Africa and APAC.

Creo's suite of devices have been designed to be used with the CROMA Advanced Energy Platform, powered by Kamaptive(TM) full-spectrum adaptive technology, a seamless, intuitive integration of multi-modal energy sources, optimised to adapt to the tissue effect required for different procedures such as resection, dissection, coagulation and ablation.

About MicroBlate(TM) Flex

Creo's MicroBlate(TM) tissue ablation technology utilises Creo's very high frequency microwave energy allowing physicians to precisely ablate diseased tissue in multiple organ types and many different clinical access methods. MicroBlate(TM) Flex is an additional soft tissue ablation device within the range, designed to ablate nodules and tumours in several soft tissue types, including the lung. MicroBlate(TM) Flex has potential to treat a number of other conditions, where a small diameter flexible device enables access into otherwise inaccessible regions of the body. MicroBlate (TM) Flex could be particularly useful to treat a range of ENT indications, including nasopharyngeal cancer and nasal polyps.

Creo's additional ablation product, MicroBlate(TM) Fine also received 510(k) clearance from the FDA in November 2020 and the first in-man clinical use of MicroBlate(TM) Fine was announced in December 2020. FDA clearance paves the way for the roll-out of these devices into the US market and with the full range of products CE marked during 2020 Creo also has access to the EU and UK markets enabling commercialisation of the GI suite.

Full details of Creo's product range can be found here:

http://www.rns-pdf.londonstockexchange.com/rns/8918P_1-2020-6-14.pdf

Craig Gulliford, Chief Executive Officer of Creo, commented:

"We are delighted to receive FDA clearance for the MicroBlate(TM) Flex device and we remain focussed on completing our programme of regulatory clearances for the full suite of advanced energy surgery products for the flexible endoscopy market. We expect to see further first clinical use of our products in various markets and we look forward to utilising our enhanced global sales and marketing capability to drive commercialisation of our range."

Enquires:

 
 Creo Medical Group plc                                          investors.creomedical.com 
 Richard Rees (CFO)                                                    [phone] 
 
 Cenkos Securities plc                                                 [phone] 
 Stephen Keys / Camilla Hume (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Paul McManus / Lianne Cawthorne                    Mob: [phone] 
                                                                                   909 238 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed the CROMA Advanced Energy Platform powered by Kamaptive(TM) full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive(TM) is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue . Kamaptive(TM) technology provides clinicians with increased flexibility, precision and controlled surgical solutions.

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by Kamaptive(TM) technology to market, enabling a wide range of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy Platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

READKABBABKDFDK

(END) Dow Jones Newswires

January 07, 2021 02:00 ET (07:00 GMT)